Drug Trial Radar · NCT06344715
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
78
Planned (sponsor's estimate)
Start
Oct 17, 2022
Primary completion
Oct 31, 2024
Study completion Oct 31, 2024
Sponsor
- Lead sponsor
- SL VAXiGENIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
SL-T10Biological
A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants
GX-I7Biological
A T-cell growth factor
PembrolizumabBiological
An immune check point inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Baseline to 23 weeks
- Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0Time frame: Baseline to 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.